Literature DB >> 11361192

Severity of knee pain does not predict a better response to an antiinflammatory dose of ibuprofen than to analgesic therapy in patients with osteoarthritis.

J D Bradley1, B P Katz, K D Brandt.   

Abstract

OBJECTIVE: To determine whether greater pain intensity at initiation of treatment predicted better response to ibuprofen than to acetaminophen in subjects with knee osteoarthritis (OA).
METHODS: Data from 182 patients with knee OA who had taken part in a 4 week randomized, double blind, parallel comparison of 4,000 mg/day acetaminophen vs either 1,200 or 2,400 mg/day ibuprofen were reanalyzed using Pearson correlation coefficients for baseline pain severity, treatment assignment, and treatment response. Pain measures were visual analog scales for overall pain, resting pain, and walking pain. Baseline pain severity was divided into low, medium, and high tertiles, and treatment related differences in pain response were sought with pairwise t tests. Two-factor analysis of variance (ANOVA) models were used to seek interactions between baseline pain severity and treatment group, which would indicate differential drug treatment responsiveness.
RESULTS: Greater baseline pain predicted greater pain relief with all 3 treatments. Patients with a high level of baseline rest pain appeared to respond better to ibuprofen 2,400 mg/day than to the other treatments, but this difference was not evident after correction for multiple statistical tests. ANOVA did not reveal significant differences in response to the 3 treatments or a significant interaction.
CONCLUSION: Our data suggest that acetaminophen and ibuprofen are comparably effective in treating knee OA pain, even when the pain is severe.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11361192

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  8 in total

Review 1.  EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT).

Authors:  K M Jordan; N K Arden; M Doherty; B Bannwarth; J W J Bijlsma; P Dieppe; K Gunther; H Hauselmann; G Herrero-Beaumont; P Kaklamanis; S Lohmander; B Leeb; M Lequesne; B Mazieres; E Martin-Mola; K Pavelka; A Pendleton; L Punzi; U Serni; B Swoboda; G Verbruggen; I Zimmerman-Gorska; M Dougados
Journal:  Ann Rheum Dis       Date:  2003-12       Impact factor: 19.103

2.  Key questions concerning paracetamol and NSAIDs for osteoarthritis.

Authors:  P Courtney; M Doherty
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

Review 3.  Acetaminophen for osteoarthritis.

Authors:  T E Towheed; L Maxwell; M G Judd; M Catton; M C Hochberg; G Wells
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

4.  Educational Intervention Effect on Pain Management Quality in Emergency Department; a Clinical Audit.

Authors:  Maryam Janati; Hamid Kariman; Elham Memary; Elnaz Davarinezhad-Moghadam; Ali Arhami-Dolatabadi
Journal:  Adv J Emerg Med       Date:  2018-01-16

Review 5.  Ibuprofen: pharmacology, efficacy and safety.

Authors:  K D Rainsford
Journal:  Inflammopharmacology       Date:  2009-11-21       Impact factor: 4.473

Review 6.  Over-the-counter analgesics in older adults: a call for improved labelling and consumer education.

Authors:  Christianne L Roumie; Marie R Griffin
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 7.  Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials.

Authors:  W Zhang; A Jones; M Doherty
Journal:  Ann Rheum Dis       Date:  2004-03-05       Impact factor: 19.103

8.  Use of ibuprofen sustained release for treating osteoarthritic pain: findings from 15 general medical practices in Egypt.

Authors:  Nabil Khalifa; Timour El-Husseini; Ahmed Morrah; Elshenawy Mostafa; Hesham Hamoud
Journal:  Open Access Rheumatol       Date:  2014-05-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.